GM1 gangliosidosis: patients with different phenotypic features and novel mutations
Journal of Pediatric Endocrinology and Metabolism · 13.04.2023
DOI: 10.1515/jpem-2022-0630 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 13.04.2023. Verfasst von Merve Emecen Sanli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Inborn Errors and Metabolism, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Lysosomal Storage Diseases, Gangliosidosis, GM1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Objectives
GM1-gangliosidosis is an autosomal recessive lysosomal storage disorder caused by beta-galactosidase deficiency encoded by GLB1. It is mainly characterized by progressive neurodegeneration due to accumulation of glycosphingolipids in central nervous system and classified into 3 forms according to the age of onset and severity of symptoms. Case presentations In this study, we described the demographic, clinical, molecular, biochemical characteristics of 4 patients from 3 unrelated families diagnosed with GM1-gangliosidosis. The ages of the patients included in the study were between 5 months and 10 years old and all were male. All families had third degree consanguinity. Two of the patients were diagnosed as infantile type and the other two siblings were diagnosed as juvenile type. Infantile type patients had coarse facial appearance, developmental delay and early neurodegeneration. Juvenile type patients had mild motor and cognitive developmental delays at the beginning, but they did not have coarse facial features. Cherry-red macula and cardiac involvement were detected in only one infantile patient, while hepatomegaly was present in both infantile type patients. Beta galactosidase enzyme levels were extremely low in all patients and two novel variants were identified in GLB1.
Conclusions
In this study, we identified four patients with different phenotypic features and two new mutations. GM1 gangliosidosis shows clinical heterogeneity according to age of onset. In some patients, developmental delay can be seen before the loss of gained functions. Therefore, this disorder should be kept in mind in patients with developmental delay who have not yet started neurodegeneration. There is no curative treatment for the disease yet, but ongoing gene therapy studies are promising for curing the disease in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Inborn Errors and Metabolism, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
- Department of medical genetics, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
ORCID-Profile: Merve Emecen Sanli
Zitieren
APA
Emecen Sanli, M., & Dogan, M. (2023). GM1 gangliosidosis: patients with different phenotypic features and novel mutations. Journal of Pediatric Endocrinology and Metabolism, 0(0). https://doi.org/10.1515/jpem-2022-0630
Vancouver
Emecen Sanli M, Dogan M. GM1 gangliosidosis: patients with different phenotypic features and novel mutations. Journal of Pediatric Endocrinology and Metabolism. 2023;0(0). doi:10.1515/jpem-2022-0630
BibTeX
@article{EmecenSanli2023,
author = {Emecen Sanli, Merve and Dogan, Mustafa},
title = {GM1 gangliosidosis: patients with different phenotypic features and novel mutations},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2023},
volume = {0},
number = {0},
doi = {10.1515/jpem-2022-0630}
}
EUVIMED